PREVENTION OF COGNITIVE IMPAIRMENT AFTER STROKE


如何引用文章

全文:

详细

The development of acute ischemic stroke is accompanied by variety of complex pathophysiological and biochemical changes in brain tissue both in the infarct area and at a distance from this area. In the case of the progression of these changes, extensive destruction of brain tissue with disruption of the structure and function of neurons, neuron loss, and development of neurological and cognitive deficits are observed. The use of neuroprotective drugs, in particular Actovegin, may cause the decrease in severity of existing neurological damage and slowing of development of delayed brain injury. The article presents the results of studies on Actovegin use in patients with cognitive impairment of various origins. It is noted that the combination of methods of secondary prevention of stroke and non-drug therapy lead to increase of treatment efficacy.

参考

  1. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М., 2001. C. 327.
  2. Siesjo B, Elmer E, Janelidze S, et al. Role and mechanisms of secondary mitochondrial failure. Acta Neurochir Suppl 1999;73:7-13.
  3. Zhao W, Chen H, Xu H. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 1999;274;34893-902.
  4. Baron J. Perfusion thresholds in human cerebral ischemia: historical perspective and therapeutic implications. Cerebrovasc Dis 2001;11(1):2-8.
  5. Lazarus R, Prettyman R, Cherryman G. White matter lesions on magnetic resonance imaging and their relationship with vascular risk factors in memory clinic attenders. Int J Geriatr Psychiatry 2005;20:274-79.
  6. Dai W, Lopez O, Carmichael O, et al. Mild cognitive impairment and Alzheimer disease: Patterns of Altered Cerebral Blood Flow at MR Imaging Radiology 2009;250(3):856-66.
  7. Shimizu S, Zhang Y, Laxamana J, et al. Concordance and discordance between brain perfusion and atrophy in frontotemporal dementia. Brain Imag Behav 2010;4:46-54.
  8. Ueno M, Tomimoto H, Akiguchi I, et al. Blood-brain barrier is disrupted in the white matter lesions in a rat model of chronic cerebral hypoperfusion. J Cereb Blood Flow Metab 2002;22:97-104.
  9. Brun A. Pathology and pathophysiology of cerebrovascular dementia: pure subgroups of obstructive and hypoperfusive etiology. Dementia 1994;5:145-47.
  10. Bladin C, Chambers B. Clinical features, pathogenesis and computed tomographic characteristics of internal watershed infarction. Stroke. 1993;24:1925-32.
  11. Hadjiev D, Mineva P. Antihypertensive treatment in elderly hypertensives without a history of stroke and the risk of cognitive disorders. Acta Neurol Scand 2008;118(3):139-45.
  12. Гусев Е.И., Камчатнов П.Р. Пластичность головного мозга в норме и патологии // Журнал невропатологии и психиатрии 2004. № 2. С. 73-80.
  13. Anderer P, Saletu B, Semlitsch H, et al. Electrical sources of P300 event-related brain potentials revealed by low resolution electromagnetic tomography. 2. Effects of nootropic therapy in age-associated memory impairment. Neuropsychobiology 1998;37(1):28-35.
  14. Бугрова С.Г. Эффективность актовегина в коррекции когнитивных нарушений при дисциркуляторной энцефалопатии // Журнал невропатологии и психиатрии им. С.С. Корсакова 2008 №. 11. С. 54-57.
  15. Herrmann W, Olszewsky W, Kuntz G. Infusionstherapie mit Actovegin bei Patienten mit ptimar degenerativer Demenz vom Alzheimer Typ und MultiinfarktDemenz. Z Geriatrie 1992;5:46-55.
  16. Kanowski S, Kinzler E, Lehmann E. Confirmed clinical efficacy of Actovegin in elderly patients with organic brain syndrome. Pharmacopsychiatry 1995;28(4):125-33.
  17. Derev'yannykh E, Bel'skaya G, Knoll E, et al. Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke. Neurosci Behav Physiol 2008;38(8):873-75.
  18. Adams H. Secondary Prevention of Atherothrombotic Events After Ischemic Stroke. Mayo Clin Proc 2009;84:43-51.
  19. Ariesen M, Algra A, Kappelle L. Antiplatelet Drugs In the Secondary Prevention After Stroke Differential Efficacy in Large Versus Small Vessel Disease? A Subgroup Analysis From ESPS-2. Stroke 2006;37:134-38.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2011
##common.cookie##